This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Quantum BioPharma's Lucid-MS, a first-in-class myelin-repair therapy for multiple sclerosis, is advancing to Phase 2 trials after successful Phase 1 safety studies. Unlike immune-targeting drugs, it works directly on nerve protection. #MultipleSclerosis #Biopharma
2026-06-30T00:02:38.022Z